Literature DB >> 2151369

Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer.

S Gundersen1, S Kvinnsland, S Lundgren, O Klepp, E Lund, O Børmer, H Høst.   

Abstract

One-hundred and seventy patients with estrogen receptor positive (greater than or equal to 10 pmol/g protein) advanced breast cancer have been treated in a prospective randomized study either with continuous tamoxifen 30 mg x 1 daily (TAM), or with TAM 30 mg x 1 daily for 8 weeks alternating with medroxyprogesterone acetate 500 mg x 2 daily for 8 weeks (TAM/HD-MPA). The response rate was 62% in the group treated with cyclic TAM/HD-MPA versus 41% in the TAM alone group (p = 0.02). There was no significant difference in duration of remissions or survival.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2151369     DOI： 10.1007/bf01812683

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


  11 in total

Review 1.  Tamoxifen in advanced breast cancer.

Authors:  H Mouridsen; T Palshof; J Patterson; L Battersby
Journal:  Cancer Treat Rev       Date:  1978-09       Impact factor: 12.111

2.  Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute.

Authors: 
Journal:  Eur J Cancer       Date:  1980-11       Impact factor: 9.162

3.  The influence of progestins on receptor levels in breast cancer metastasis.

Authors:  S Lundgren; S Kvinnsland; J E Varhaug; E Utaaker
Journal:  Anticancer Res       Date:  1987 Jan-Feb       Impact factor: 2.480

4.  Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer.

Authors:  M Namer; C Lalanne; E E Baulieu
Journal:  Cancer Res       Date:  1980-05       Impact factor: 12.701

5.  Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment.

Authors:  A Howell; R N Harland; D M Barnes; A D Baildam; M J Wilkinson; E Hayward; R Swindell; R A Sellwood
Journal:  Cancer Res       Date:  1987-01-01       Impact factor: 12.701

6.  High-dose megestrol acetate in the treatment of postmenopausal women with advanced breast cancer.

Authors:  N S Tchekmedyian; N Tait; J Aisner
Journal:  Semin Oncol       Date:  1986-12       Impact factor: 4.929

7.  Characterization and assay of progesterone receptor in human mammary carcinoma.

Authors:  M F Pichon; E Milgrom
Journal:  Cancer Res       Date:  1977-02       Impact factor: 12.701

8.  Effects of tamoxifen on estrogen and progesterone receptors in human breast cancer.

Authors:  N Waseda; Y Kato; H Imura; M Kurata
Journal:  Cancer Res       Date:  1981-05       Impact factor: 12.701

9.  Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases.

Authors:  M R Williams; J H Todd; I O Ellis; C S Dowle; J L Haybittle; C W Elston; R I Nicholson; K Griffiths; R W Blamey
Journal:  Br J Cancer       Date:  1987-01       Impact factor: 7.640

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640
View more
  4 in total

Review 1.  The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer.

Authors:  Michael W Drazer; Walter M Stadler
Journal:  Cancer J       Date:  2016 Sep/Oct       Impact factor: 3.360

Review 2.  Hot flashes: aetiology and management.

Authors:  D Barton; C Loprinzi; D Wahner-Roedler
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  The effects of cyclosporin A, tamoxifen, and medroxyprogesterone acetate on the enhancement of adriamycin cytotoxicity in primary cultures of human breast epithelial cells.

Authors:  J A Claudio; J T Emerman
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Tamoxifen and megestrol acetate for postmenopausal breast cancer: diverging effects on liver proteins, androgens, and glucocorticoids.

Authors:  L Löfgren; B Wallberg; N Wilking; T Fornander; L E Rutqvist; K Carlström; B von Schoultz; E von Schoultz
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.